'Takeda, Lilly Rejected by Supreme Court on Actos Fraud Lawsuit' - Bloomberg

The U.S. Supreme Court has rejected an appeal from Takeda Pharmaceutical Co. and Eli Lilly and Co. concerning a fraud lawsuit related to their diabetes drug, Actos. This decision upholds lower court rulings that found the companies liable for misleading marketing practices. The ruling may have significant implications for both companies, particularly in terms of potential financial liabilities and reputational impact.